Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4 Purity >98.0% (HPLC) Lenvatinib Mesylate Intermediate Factory
Ruifu Chemical Supply Lenvatinib Mesylate Intermediates With High Purity
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Pangalan ng kemikal | Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate |
Mga kasingkahulugan | Lenvatinib Impurity 47;4-Chloro-7-Methoxyquinoline-6-Carboxylic Acid Methyl Ester;4-Chloro-7-Methoxy-6-Quinolinecarboxylic Acid Methyl Ester;Lenvaint-D |
Numero ng CAS | 205448-66-4 |
Numero ng CAT | RF-PI1970 |
Katayuan ng Stock | Sa Stock, Production Scale Hanggang Tonelada |
Molecular Formula | C12H10ClNO3 |
Molekular na Timbang | 251.67 |
Punto ng pag-kulo | 377.4±37.0℃ |
Densidad | 1.320±0.06 g/cm3 |
Tatak | Ruifu Chemical |
item | Mga pagtutukoy |
Hitsura | Off-White hanggang Yellow Solid Powder |
1 H NMR Spectrum | Naaayon sa Istruktura |
Kadalisayan / Paraan ng Pagsusuri | >98.0% (HPLC) |
Pagkawala sa Pagpapatuyo | <1.00% |
Kabuuang mga Dumi | <2.00% |
Pamantayan sa Pagsubok | Enterprise Standard |
Paggamit | Intermediate/Dumi ng Lenvatinib Mesylate (CAS: 857890-39-2) |
Package: Bote, Aluminum foil bag, 25kg/Cardboard Drum, o ayon sa pangangailangan ng customer
Kondisyon ng Imbakan:Mag-imbak sa mga selyadong lalagyan sa malamig at tuyo na lugar;Protektahan mula sa liwanag at kahalumigmigan
Ang Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate (CAS: 205448-66-4) ay isang intermediate ng Lenvatinib Mesylate (CAS: 857890-39-2).Ang Lenvatinib ay isang gamot sa thyroid cancer na binuo ng Eisai Corporation ng Japan (Code: E7080), na kabilang sa inhibitor ng oral multi-receptor tyrosine kinase (RTK) at maaaring pigilan ang aktibidad ng kinase ng vascular endothelial growth factor Receptors R1 (FLT1), VEG-FR2 (KDR), R3 (FLT4).Ang Lenvatinib ay maaari ding pigilan ang paglahok ng iba pang mga RTK sa pathological angiogenesis, paglaki ng tumor, at pag-unlad ng kanser maliban sa kanilang mga normal na cellular function kabilang ang fibroblast growth factor (FGF) receptors FGFR1, 2, 3, at 4;platelet-derived growth factor receptor (PDGFR [alpha]), KIT, at RET.[Mga indikasyon]: Ang Lenvatinib ay angkop para sa paggamot ng mga pasyente ng thyroid cancer ng lokal na pag-ulit o uri ng metastasis, uri ng progresibo at radioactive iodine-refractory differentiated type.